# OnCo record paper-laktionov-prolgolimab-domajor-ejc-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-laktionov-prolgolimab-domajor-ejc-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-laktionov-prolgolimab-domajor-ejc-2025" ;
  schema:name "DOMAJOR: prolgolimab with chemotherapy first line in advanced non-squamous lung cancer"@en ;
  schema:description "A 292-patient randomised phase 3 in Russia, China, Hungary and Slovakia in which adding the Russian PD-1 antibody prolgolimab to pemetrexed and platinum roughly halved the risk of death, with the benefit holding in PD-L1-negative tumours."@en ;
  schema:url <https://onco.cc/key-papers/paper-laktionov-prolgolimab-domajor-ejc-2025/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.ejca.2025.115255>, <https://pubmed.ncbi.nlm.nih.gov/39879779/>, <https://clinicaltrials.gov/study/NCT03912389> ;
  schema:sameAs <https://doi.org/10.1016/j.ejca.2025.115255> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Laktionov K, Smolin A, Stroyakovskiy D, et al." ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/bcd-100/> ;
  onco:companies <https://onco.cc/companies/biocad/> ;
  onco:journals <https://onco.cc/journals/european-journal-of-cancer/> .